Eloxx Pharma Q2 net loss $4.3M; cash only into Q4 2023; ELX-02 positive biopsy data

Eloxx Pharmaceuticals, Inc.

2023-Q2 EPS reported -$4.83 vs consensus -$1.57 ▼ miss (-207.5%)

Net loss of $4.3M ($1.96 EPS) vs $10.6M ($4.90 EPS) in prior-year quarter.
Cash $4.3M at June 30; raised $1.7M gross via ATM program post-quarter.
All 3 patients on ELX-02 showed improved podocyte foot process effacement in kidney biopsies; company plans pivotal Alport trial pending funding.
FDA cleared IND for ZKN-013 SAD study in RDEB; first dosing expected by end 2023.
Nasdaq extended compliance deadline for $35M market value listing rule to October 9, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eloxx Pharmaceuticals, Inc. reported financial results for the three months ended June 30, 2023.

Period: the three months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and providing a business update.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.